NeuroPace (NPCE) Total Non-Current Liabilities (2020 - 2021)
NeuroPace (NPCE) posted quarterly Total Non-Current Liabilities of $60.1 million for Q4 2021, down 3.12% year-over-year from $62.0 million in Q4 2020, and up 1.29% quarter-over-quarter from $59.3 million in Q3 2021.
NeuroPace (NPCE) Total Non-Current Liabilities (2020 - 2021) Analysis & Trends
NeuroPace's Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $60.1 million for Q4 2021.
- In Q4 2021, Total Non-Current Liabilities fell 3.12% year-over-year to $60.1 million; the TTM figure through Dec 2021 stood at $60.1 million (down 3.12% YoY), while the FY2021 annual figure was $60.1 million, down 3.12% from the prior year.
- Total Non-Current Liabilities for Q4 2021 stood at $60.1 million, up from $59.3 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $65.1 million in Q1 2021, with the low at $58.1 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.49 Bn | 193.88 Bn | 7.27 Bn | - |
| 2 | Stryker | 127.80 Bn | 124.32 Bn | 4.50 Bn | 21.28 Bn |
| 3 | Medtronic | 118.98 Bn | 109.76 Bn | 6.41 Bn | 40.90 Bn |
| 4 | Boston Scientific | 73.58 Bn | 73.04 Bn | 3.85 Bn | 42.74 Bn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 2.57 Bn |
| 6 | Dexcom | 34.34 Bn | 32.39 Bn | 830.00 Mn | 3.68 Bn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.66 Bn | 2.18 Bn | 23.89 Bn |
| 8 | Koninklijke Philips | 26.37 Bn | 23.05 Bn | 4.55 Bn | 9.07 Bn |
| 9 | Steris | 23.07 Bn | 22.59 Bn | 684.20 Mn | 3.44 Bn |
| 10 | NeuroPace | 463.14 Mn | 411.44 Mn | 18.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 60.06 Mn |
| Sep 30, 2021 | 59.30 Mn |
| Jun 30, 2021 | 58.06 Mn |
| Mar 31, 2021 | 65.06 Mn |
| Dec 31, 2020 | 61.99 Mn |